Skip to content

Coriolus mushroom

The butterfly tramete is a mushroom that is also known as the Coriolus mushroom. The fruiting body and other parts of the plant have long been used as medicine in folk medicine. Recently, scientists have begun to identify the constituents of the butterfly tramete that could act as active pharmaceutical ingredients. Two of these are polycaccharide peptide (PSP) and polysaccharide crestin (PSK). Scientists believe that these chemicals may be able to fight cancer and boost the function of the immune system. Butterfly Tramete, PSP and PSK are used to stimulate the function of the immune system, to treat herpes, chronic fatigue syndrome, hepatitis and lung diseases, to reduce mucus formation, to improve bodybuilding results, to increase energy, to treat bark lichen and pyoderma, to treat infections of the upper respiratory tract, urinary tract and digestive tract, to treat liver diseases including hepatitis, to reduce the toxic effects and pain of chemotherapy and radiation therapy, to improve the quality of life of cancer patients and to increase appetite.

How does Butterfly Tramete work?

Butterfly Tramete contains Polysaccharide Peptide (PSP) and Polysaccharide Krestin (PSK), which may be able to fight tumor growth and improve immune system function.

How effective is the butterfly tramete?

Butterfly Tramete may be effective in the treatment of cancer in combination with chemotherapy. Taking Polysaccharide Krestin (PSK), a substance found in butterfly tramete, may improve the response of some patients to chemotherapy. PSK has been used in Japan for several decades for breast cancer, esophageal cancer, stomach cancer, lung cancer, liver cancer, colorectal cancer and nasopharyngeal cancer with varying results. There is insufficient scientific data to make a statement regarding the effectiveness of butterfly weed for herpes, chronic fatigue syndrome, hepatitis, lung disease, bark lichen, skin infections including pyoderma, urinary tract infections, digestive tract infections and poor appetite, as well as for stimulating immune system function and improving bodybuilding results. Further scientific research is needed to evaluate the effectiveness of butterfly weed in these applications.

Safety and side effects

Butterfly Tramete is potentially safe and harmless for most people. There have been no reports of side effects to date. However, people receiving chemotherapy in combination with a chemical called PSK (which is extracted from butterfly tramete ) have experienced nausea, low red blood cell counts and liver problems. It is not clear whether these side effects were caused by the chemotherapy or PSK.

Precautions and warnings

Pregnancy and lactation: Not enough is known about the use of butterfly weed during pregnancy and lactation. For this reason, pregnant and breastfeeding women should avoid Butterfly Tramete.

Interactions

At the moment there is no information available on interactions between butterfly tramete and medications or supplements.

Dosage

The following dosages have been investigated in scientific studies:

Oral

  • For cancer in addition to chemotherapy: 3 grams of PSK, the ingredient believed to fight cancer, taken daily.

References

  1. Collins RA, Ng TB. Polysaccharopeptide from Coriolus versicolor has potential for use against human immunodeficiency virus type 1 infection. Life Sci 1997;60:PL383-7.
  2. Dong Y, Kwan CY, Chen ZN, et al. Antitumor effects of a refined polysaccharide peptide fraction isolated from Coriolus versicolor: in vitro and in vivo studies. Res Commun Mol Pathol Pharmacol 1996;92:140-8.
  3. Dong Y, Yang MM, Kwan CY. In vitro inhibition of proliferation of HL-60 cells by tetrandrine and coriolus versicolor peptide derived from Chinese medicinal herbs. Life Sci 1997;60:PL135-40.
  4. Fukushima M. Adjuvant therapy of gastric cancer: the Japanese experience. Semin Oncol 1996;23:369-78.
  5. Go P, Chung CH. Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx. J Int Med Res 1989;17:141-9.
  6. Gong S, Zhang HQ, Yin WP, et al. Involvement of interleukin-2 in analgesia produced by Coriolus versicolor polysaccharide peptides. Chung Kuo Yao Li Hsueh Pao 1998;19:67-70.
  7. Harada M, Matsunaga K, Oguchi Y, et al. Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut associated lymphoid tissue (GALT) of specific-pathogen-free mice. Int J Cancer 1997;70:362-72.
  8. Hayakawa K, Mitsuhashi N, Saito Y, et al. Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Cancer Detect Prev 1997;21:71-7.
  9. Iino Y, Yokoe T, Maemura M, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res 1995;15:2907-11.
  10. Kanoh T, Saito K, Matsunaga K, et al. Enhancement of the antitumor effect by the concurrent use of a monoclonal antibody and the protein bound polysaccharide PSK in mice bearing a human cancer cell line. In Vivo 1994;8:241-5.
  11. Kim HS, Kacew S, Lee BM. In vitro chemopreventive effects of plant polysaccharides (Aloe barbadensis miller, Lentinus edodes, Ganoderma lucidum and Coriolus versicolor). Carcinogenesis 1999;20:1637-40.
  12. Kobayashi H, Matsunaga K, Oguchi Y. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiol Biomarkers Prev 1995;4:275-81.
  13. Kondo T, Sakamoto J, Nakazato H. Alternating immunochemotherapy of advanced gastric carcinoma: a randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection. Biotherapy 1991;3:287-95.
  14. Maehara Y, Inutsuka S, Takeuchi H, et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer Chemother Pharmacol 1993;33:171-5.
  15. Mitomi T, Tsuchiya S, Iijima N, et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum 1992;35:123-30.
  16. Mizutani Y, Yoshida O. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer. J Urol 1991;145:1082-7.
  17. Morimoto T, Ogawa M, Orita K, et al. Postoperative adjuvant randomized trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan. Eur J Cancer 1996;32A:235-42.
  18. Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 1994;343:1122-6.
  19. Ng TB, Chan WY. Polysaccharopeptide from the mushroom Coriolus versicolor possesses analgesic activity but does not produce adverse effects on female reproductive or embryonic development in mice. Gen Pharmacol 1997;29:269-73.
  20. Ng TB. A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol 1998;30:1-4.
  21. Nio Y, Tsubono M, Tseng CC, et al. Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer. Biotherapy 1992;4:117-28.
  22. Ogoshi K, Satou H, Isono K, et al. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. Am J Clin Oncol 1995;18:216-22.
  23. Qian ZM, Xu MF, Tang PL. Polysaccharide peptide (PSP) restores immunosuppression induced by cyclophosphamide in rats. Am J Chin Med 1997;25:27-35.
  24. Sugimachi K, Maehara Y, Ogawa M, et al. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol 1997;40:233-8.
  25. Suto T, Fukuda S, Moriya N, et al. Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33 Suppl:S145-8.
  26. Tochikura TS, Nakashima H, Hirose K, et al. A biological response modifier, PSK, inhibits human immunodeficiency virus infection in vitro. Biochem Biophys Res Commun 1987;148:726-33.
  27. Toi M, Hattori T, Akagi M, et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer 1992;70:2475-83.
  28. Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 1990;31:261-8.
  29. Tsukagoshi S, Hashimoto Y, Fujii G, et al. Krestin (PSK). Cancer Treat Rev 1984;11:131-55.
  30. Wang HX, Ng TB, Liu WK, et al. Polysaccharide-peptide complexes from the cultured mycelia of the mushroom Coriolus versicolor and their culture medium activate mouse lymphocytes and macrophages. Int J Biochem Cell Biol 1996;28:601-7.
  31. Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 1999;19:65-96.
  32. Yeung JH, Chiu LC, Ooi VE. Effect of polysaccharide peptide (PSP) on glutathione and protection against paracetamol-induced hepatotoxicity in the rat. Methods Find Exp Clin Pharmacol 1994;16:723-9.
  33. Yokoe T, Iino Y, Takei H, et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. Anticancer Res 1997;17:2815-8.